ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Down 8.5% in January

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was the target of a large decline in short interest in January. As of January 15th, there was short interest totalling 2,150,000 shares, a decline of 8.5% from the December 31st total of 2,350,000 shares. Based on an average trading volume of 252,300 shares, the days-to-cover ratio is currently 8.5 days.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ANIP shares. HC Wainwright reissued a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Piper Sandler initiated coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target on the stock. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Truist Financial boosted their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Finally, Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $77.71.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock traded down $0.46 during trading on Monday, hitting $58.18. 28,360 shares of the stock were exchanged, compared to its average volume of 165,579. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -105.79 and a beta of 0.74. ANI Pharmaceuticals has a 1-year low of $52.50 and a 1-year high of $70.81. The company has a fifty day moving average price of $56.61 and a 200-day moving average price of $58.53.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. During the same period in the prior year, the firm posted $1.05 EPS. ANI Pharmaceuticals’s quarterly revenue was up 12.5% on a year-over-year basis. As a group, equities analysts predict that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the transaction, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at $2,943,540. This trade represents a 2.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Nikhil Lalwani sold 33,481 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the transaction, the chief executive officer now owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. The trade was a 8.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,381 shares of company stock valued at $2,441,556 in the last quarter. 12.70% of the stock is currently owned by corporate insiders.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors have recently modified their holdings of ANIP. Sei Investments Co. lifted its holdings in shares of ANI Pharmaceuticals by 27.8% in the 2nd quarter. Sei Investments Co. now owns 14,473 shares of the specialty pharmaceutical company’s stock worth $922,000 after purchasing an additional 3,152 shares in the last quarter. Marshall Wace LLP bought a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $253,000. AQR Capital Management LLC boosted its stake in ANI Pharmaceuticals by 44.8% during the 2nd quarter. AQR Capital Management LLC now owns 17,527 shares of the specialty pharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 5,419 shares during the last quarter. Millennium Management LLC increased its holdings in ANI Pharmaceuticals by 1,005.8% during the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock worth $14,651,000 after purchasing an additional 209,272 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of ANI Pharmaceuticals by 14.6% in the second quarter. The Manufacturers Life Insurance Company now owns 9,498 shares of the specialty pharmaceutical company’s stock worth $605,000 after purchasing an additional 1,211 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.